Pharma BD Deal Intelligence
A multi-phase licensing collaboration turned Dragonfly's TriNKET platform into a seven-program pipeline for BMS, expanding from a single 2017 hematology deal to solid tumors, autoimmune disease, and neuroinflammation by 2023—though the $475 million figure covers just the added IL-12 program, not the full multi-year partnership.
Dragonfly Therapeutics announces strategic collaboration with Celgene to discover and develop novel natural killer (NK) cell-based immunotherapies using…
BMS licenses IL-12 from Dragonfly in $475 million deal. Dragonfly receives $475 million in near-term upfront payments for DF6002 program plus milestone and…
Dragonfly Therapeutics announces sixth Dragonfly TriNKET opt-in by Bristol Myers Squibb, bringing total licensed drugs to seven including the novel…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Multi-phase collaboration between Celgene (later BMS after 2019 acquisition) and Dragonfly Therapeutics for TriNKET NK cell engager immunotherapies. The original June 2017 collaboration focused on hematology malignancies. The partnership expanded multiple times: 2018 expansion doubled programs to include solid tumors; 2020 added a $475 million IL-12 program (DF6002/BMS-986415); and by 2023, BMS had opted into six TriNKET drug candidates plus the IL-12 cytokine, for seven total licensed programs spanning hematologic cancers, solid tumors, autoimmune disease, and neuroinflammation. Individual opt-in payments in the $25-28 million range per TriNKET program.
1.9M US cases/yr · $200.0B Global oncology market
Solid tumors encompass all non-hematologic cancers. IO checkpoint inhibitors, targeted therapies, and ADCs have transformed treatment across multiple tumor types. Pan-tumor approvals (e.g., MSI-H, NTRK) enable biomarker-driven approaches.
IO combinations, ADCs, and bispecifics driving growth. Tumor-agnostic approvals expanding. Key platforms: Merck (Keytruda), BMS (Opdivo), Roche (Tecentriq), Daiichi Sankyo/AZ (Enhertu).
190K US cases/yr · $60.0B Global hematologic oncology
Hematologic malignancies include leukemias, lymphomas, and myelomas. CAR-T, bispecifics, BTK inhibitors, and venetoclax have transformed treatment across subtypes.
CAR-T therapy, bispecific antibodies, BTK inhibitors, BCL-2 inhibitors, anti-CD38/CD20 antibodies. Key players: BMS, J&J, Roche, AbbVie, Gilead/Kite, Pfizer.
$80.0B Global autoimmune therapeutics
Autoimmune diseases encompass >80 conditions where the immune system attacks the body. The market is dominated by anti-TNFs, IL-inhibitors, JAK inhibitors, and emerging cell therapies.
Anti-TNF (adalimumab, infliximab), IL-17/23 inhibitors, JAK inhibitors, B-cell depleting therapies. CAR-T for severe autoimmune diseases emerging. Key players: AbbVie, J&J, Pfizer, Roche, BMS.
Celgene (later BMS) partnered with Dragonfly for TriNKET NK cell engager immunotherapies.
DF6002 (IL-12), DF1001 (HER2), DF9001 (EGFR) programs advancing. Multi-phase expansion from hematology to solid tumors.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Dragonfly Therapeutics Inc. (this deal) | 2017 | $475M | 60 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2017 deals · Bristol-Myers Squibb Company deals · Immunology deals